-
Mashup Score: 5
The combination treatment is the first and only regimen to show a survival benefit that surpasses the current standard of care for EGFR-mutated lung cancer.
Source: www.ilcn.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 16
Drs. Joelle Fathi and Mahdi Sheikh summarize the growing body of evidence that shows quitting smoking after diagnosis improves survival.
Source: www.ilcn.orgCategories: General Medicine News, Oncologists1Tweet-
Discover why experts recommend smoking cessation as a first-line intervention for lung cancer. Explore the latest data in ILCN: https://t.co/0gOW6hXjTw #LCSM
-
-
Mashup Score: 5Experts Share New Insights, Key Updates During Final Plenary Session of the 2024 ACLC - ILCN.org (ILCN/WCLC) - 5 day(s) ago
Takeaways included updates from the CheckMate 816 study, advances in technology, the role of metabolites and mobile CT screening in predicting cancer risk, and the importance of biomarkers for guiding optimal treatment.
Source: www.ilcn.orgCategories: General Medicine News, Onc News and JournalsTweet-
Catch up on the latest insights and key takeaways from the final plenary session of the 2024 ACLC in Hong Kong. Visit ILCN for more: https://t.co/cyzeMFaBcV #LCSM
-
-
Mashup Score: 1In Brief for January 8, 2025 - ILCN.org (ILCN/WCLC) - 14 day(s) ago
The US FDA approves ensartinib for ALK-positive NSCLC and provides an updated regulatory review of subcutaneous amivantamab.
Source: www.ilcn.orgCategories: General Medicine News, Oncologists1Tweet-
ICYMI: The US FDA approves ensartinib for ALK-positive NSCLC and provides an updated regulatory review of subcutaneous amivantamab. More updates in ILCN: https://t.co/g5vcoT9ktr #LCSM
-
-
Mashup Score: 4Research to Watch: Lurbinectedin-Atezolizumab Combination Demonstrates Significant OS, PFS Benefits - ILCN.org (ILCN/WCLC) - 15 day(s) ago
Promising results from the phase III IMforte trial reveal a potential first-line therapy for patients with ES-SCLC.
Source: www.ilcn.orgCategories: General Medicine News, Oncologists1Tweet-
Promising results from the phase III IMforte trial reveal a potential first-line therapy for patients with ES-SCLC. Find out more in ILCN: https://t.co/vR7P0lRUOt #LCSM
-
-
Mashup Score: 4
During the opening plenary session at the 2024 Asia Conference on Lung Cancer, experts offered their perspectives on clinical trials, combination therapies, and research initiatives.
Source: www.ilcn.orgCategories: General Medicine News, Oncologists1Tweet-
Delve into highlights from the opening plenary session at the 2024 Asia Conference on Lung Cancer. Visit ILCN for more details: https://t.co/fdnJfMuXPh #LCSM
-
-
Mashup Score: 19No “Known” Risk Factors: The Health Consequences of Radiation Therapy - ILCN.org (ILCN/WCLC) - 17 day(s) ago
Heidi Nafman-Onda, founder of The White Ribbon Project, shares her experience discovering and grappling with the long-term effects of radiation therapy and addresses the need for coordinated survivorship care.
Source: www.ilcn.orgCategories: General Medicine News, Oncologists1Tweet-
Heidi Nafman-Onda, founder of The White Ribbon Project, shares her experience with the long-term effects of radiation therapy. Learn more in ILCN: https://t.co/r7J9yuRMUx #LCSM
-
-
Mashup Score: 4Emerging Biomarkers Have Potential to Refine Patient Selection, Improve Immunotherapy Strategies - ILCN.org (ILCN/WCLC) - 21 day(s) ago
Drs. Marina Chiara Garassino, Sulin Wu, and Faith Abodunrin offer insights from the RELATIVITY-104 and GALAXIES Lung-201 Trials.
Source: www.ilcn.orgCategories: General Medicine News, Oncologists1Tweet-
Drs. Marina Chiara Garassino, Sulin Wu, and Faith Abodunrin offer insights from the RELATIVITY-104 and GALAXIES Lung-201 trials. Read more in ILCN: https://t.co/xNDfZIKMXR #LCSM
-
-
Mashup Score: 0In Brief for December 18, 2024 - ILCN.org (ILCN/WCLC) - 1 month(s) ago
European Medicines Agency recommends repotrectinib for ROS1-positive NSCLC; FDA approves therapies for NSCLC, LS-SCLC as well as a new diagnostic tool for identifying MET exon 14 skipping alterations.
Source: www.ilcn.orgCategories: General Medicine News, Oncologists1Tweet-
ICYMI: Don’t miss the latest recommendations from the EMA and approvals from the U.S. FDA. For more regulatory news, visit ILCN: https://t.co/Q5JHUY0qEN #LCSM
-
-
Mashup Score: 10IASLC, LCRF Announce First Recipients of Joint Team Science Award Aimed at Finding a Cure for Oncogene-Driven Lung Cancers - ILCN.org (ILCN/WCLC) - 1 month(s) ago
Dr. David Barbie and his team will receive a 4-year, $2.5 million grant to support their research on immune-based approaches to target drug-resistant cancer cells.
Source: www.ilcn.orgCategories: General Medicine News, Oncologists1Tweet-
The IASLC and LCRF announce the first recipients of the IASLC-LCRF Team Science Award. Visit ILCN to learn more: https://t.co/BWfTnvz5zE #LCSM
-
Is there a new standard of care for EGFR-mutated lung cancer? Read the latest findings from the MARIPOSA trial in ILCN: https://t.co/YfntqKSYZC #LCSM